US outlines exemption steps for pharmaceutical tariffs
( May 13, 2026, 20:39 GMT | Official Statement) -- MLex summary: The US Commerce Department's Bureau of Industry and Security submitted rules and guidelines for exemptions from a 100 percent pharmaceutical tariff under Section 232, outlining how eligible companies can apply who onshore manufacturing and/or reach a deal with the US to reduce drug prices to most favored nation rates. The notice indicates companies must file detailed applications with information about investment commitments, onshoring and US sales data. BIS also ruled out products a manufacturer acquires or makes after April 2, 2026. The pharmaceutical tariffs take effect on Sept. 29 and the exemptions last until Jan. 20, 2029, for companies that reach deals on most favored nation rates.See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.